RESUMO
Management of non-Hodgkin's lymphomas (NHL) has been significantly changed during last 40 years from radiotherapy to modern polychemotherapy with application of monoclonal antibodies. A ten year experience of the treatment of patients with B-cell NHL with rituximab application was accumulated in National Cancer Institute. The group of patients with NHL, who were treated in oncohematology department in the period from 2001 to 2010, was chosen for study of the efficacy of the treatment with rituximab. The immediate and distant results of the treatment were evaluated in this group of patients. The usage of the polychemotherapy with rituximab was highly efficient in the treatment of primary and relapsed patients with NHL. This group shows high rate of the immediate and distant results of treatment.
Assuntos
Anticorpos Monoclonais Murinos/uso terapêutico , Antígenos CD20/imunologia , Antineoplásicos/uso terapêutico , Linfócitos B/imunologia , Linfoma não Hodgkin/tratamento farmacológico , Linfoma não Hodgkin/imunologia , Prevenção Secundária , Adulto , Idoso , Anticorpos Monoclonais Murinos/administração & dosagem , Antígenos CD20/metabolismo , Antineoplásicos/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Linfócitos B/citologia , Biópsia , Intervalo Livre de Doença , Esquema de Medicação , Feminino , Humanos , Estudos Longitudinais , Linfoma não Hodgkin/mortalidade , Linfoma não Hodgkin/patologia , Masculino , Pessoa de Meia-Idade , Rituximab , Linfócitos T/citologia , Linfócitos T/imunologia , Resultado do Tratamento , UcrâniaRESUMO
The treatment of patients with refractory forms of Hodgkin's lymphomas in combination with chemo-radiotherapy is priority. Nevertheless, chemotherapy has to include multicomponent schemes and radiation therapy should be an addition and consolidative method to chemotherapy.